Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

Neurocrine Biosciences, Inc. (NBIX)

Today's Latest Price: $99.01 USD

2.48 (2.57%)

Updated Oct 23 4:00pm

Add NBIX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NBIX Stock Summary

  • NBIX's price/sales ratio is 8.89; that's higher than the P/S ratio of 84.94% of US stocks.
  • Over the past twelve months, NBIX has reported earnings growth of 400.63%, putting it ahead of 96.16% of US stocks in our set.
  • As for revenue growth, note that NBIX's revenue has grown 66.15% over the past 12 months; that beats the revenue growth of 92.09% of US companies in our set.
  • Stocks that are quantitatively similar to NBIX, based on their financial statements, market capitalization, and price volatility, are RP, FLGT, APPS, FORM, and MASI.
  • Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $99.01 52-week high $136.26
Prev. close $96.53 52-week low $72.14
Day low $96.38 Volume 502,900
Day high $99.16 Avg. volume 822,011
50-day MA $104.71 Dividend yield N/A
200-day MA $107.32 Market Cap 9.23B

Neurocrine Biosciences, Inc. (NBIX) Company Bio

Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.

NBIX Latest News Stream

Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream

Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Impact of Covid-19 on Endometriosis Market Insights 2020 Overview, Competitive Players & Forecast 2027 | Johnson & Johnson Services Inc., Bayer AG, Neurocrine Biosciences Inc., Meditrina Pharmaceuticals Inc.

The Global endometriosis market is forecast to reach USD 2.42 Billion by 2026, according to a new report by Reports and Data. Endometriosis is the resultant of the growth of endometrial tissue on bowel, ovaries, and tissues lining the pelvis. The hormonal

OpenPR | September 29, 2020

Axovant Offers An Interesting Risk-Reward Proposition

Axovant Gene Therapies (AXGT) is a gene therapy company focused on treating neurodegenerative diseases, including Parkinson's Disease. Despite being in early clinical stages and being relatively underfunded, in my opinion, at today's valuation, it offers a very interesting risk/reward proposition. I explain why in this article. Axovant's Product Candidates (source)...

Amit Ghate on Seeking Alpha | September 28, 2020

Neurocrine Biosciences Is The Developer Of A New Cure For Parkinson's Disease

What does the company do? Neurocrine Biosciences (NBIX) is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis and uterine...

Russian Rocket on Seeking Alpha | September 26, 2020

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS® (opicapone) capsules decreased "off" time and increased "on" time without troublesome…

PR Newswire | September 11, 2020

Looking Into Neurocrine Biosciences's Return On Capital Employed

Looking at Q2, Neurocrine Biosciences (NASDAQ: NBIX) earned $76.60 million, a 30.05% increase from the preceding quarter. Neurocrine Biosciences also posted …

Benzinga | August 28, 2020

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo 1.34%
3-mo -21.42%
6-mo 0.39%
1-year 0.67%
3-year 66.82%
5-year 103.06%
YTD -7.89%
2019 50.53%
2018 -7.96%
2017 100.49%
2016 -31.59%
2015 153.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6667 seconds.